北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科  > 期刊论文
学科主题: 临床医学
题名:
Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
作者: Jin, Xuan2; Ding, Huirong3; Ding, Ning1; Fu, Zhiying1; Song, Yuqin1; Zhu, Jun1
关键词: Complement ; Polymorphism ; Rituximab ; DLBCL ; C1qA
刊名: JOURNAL OF HEMATOLOGY & ONCOLOGY
发表日期: 2012-08-16
DOI: 10.1186/1756-8722-5-51
卷: 5
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Hematology
研究领域[WOS]: Oncology ; Hematology
关键词[WOS]: CHRONIC LYMPHOCYTIC-LEUKEMIA ; CHEMOTHERAPY PLUS RITUXIMAB ; C1Q BINDING-SITE ; ELDERLY-PATIENTS ; IN-VIVO ; EFFECTOR MECHANISMS ; ANTIBODY ; ACTIVATION ; EXPRESSION ; INHIBITORS
英文摘要:

Background: The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to rituximab-based therapy in diffuse large B cell lymphoma (DLBCL). The purpose of this study was to explore the relationship between C1qA([276]) polymorphism and the clinical response to standard frontline treatment with R-CHOP in DLBCL patients.

Methods: Genotyping for C1qA([276A/G]) was done in 164 patients with DLBCL. 129 patients treated with R-CHOP as frontline therapy (R >= 4 cycles) were assessable for the efficacy.

Results: Patients with homozygous A were found to have a higher overall response rate than those with heterozygous or homozygous G alleles (97.3% vs. 83.7%, P = 0.068). The complete response rate in patients with homozygous A was statistically higher than that in AG and GG allele carriers (89.2% vs. 51.1%, P = 0.0001). The overall survival of patients with homozygous A was longer than that of the G allele carriers (676 days vs. 497 days, P = 0.023). Multivariate Cox regression analysis showed that C1qA A/A allele was an independent favorable prognostic factor for DLBCL patients treated with R-CHOP as first-line therapy.

Conclusion: These results suggest that C1qA polymorphism may be a biomarker to predict response to R-CHOP as frontline therapy for DLBCL patients.

语种: 英语
所属项目编号: 30973484
项目资助者: National Science Foundation Committee of China
WOS记录号: WOS:000309879700001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/67061
Appears in Collections:北京大学临床肿瘤学院_淋巴肿瘤内科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Hosp 1, Dept Internal Med Oncol, Beijing 100034, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Cent Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China

Recommended Citation:
Jin, Xuan,Ding, Huirong,Ding, Ning,et al. Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY,2012,5.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Jin, Xuan]'s Articles
[Ding, Huirong]'s Articles
[Ding, Ning]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Jin, Xuan]‘s Articles
[Ding, Huirong]‘s Articles
[Ding, Ning]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace